Clopidogrel (ISCOVER, PLAVIX): Bad choice after aspirin-induced bleeding ulcers
Glucose-insulin-potassium infusions without benefit after myocardial infarction

Solifenacin (VESIKUR) and Darifenacin (EMSELEX) for overactive bladder

Drug therapy of cancer pain (I)

Cardiotoxicity of Etoricoxib (ARCOXIA)
Reviparin (CLIVARIN) after myocardial infarction
Duloxetin (YENTREVE): Not licensed for stress incontinence by FDA

Frequent serious local adverse events after pneumococcal revaccination

Ezetemib (EZETROL): Hepatitis, rhabdomyolysis and other serious adverse events
Osteonecrosis of the jaw associated with use of bisphosphonates: a class effect?
Increased mortality associated with Alzheimer-drug Galantamin (REMINYL)